(3S)‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine (IRL752) —a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent-Reference-Cited by-同舟云学术

(3S)‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine (IRL752) —a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent

Published:2020-06-30 Issue:3 Volume:374 Page:404-419
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Hjorth S.,Waters S.^ORCID,Waters N.,Tedroff J.,Svensson P.,Fagerberg A.,Edling M.,Svanberg B.,Ljung E.,Gunnergren J.,McLean S.L.,Grayson B.,Idris N.F.,Neill J.C.,Sonesson C.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference97 articles.

1. Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest Study

2. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm

3. Catecholamine modulation of prefrontal cortical cognitive function

4. Catecholamine Influences on Dorsolateral Prefrontal Cortical Networks

5. Differential regulation of psychostimulant-induced gene expression of brain derived neurotrophic factor and the immediate-early geneArcin the juvenile and adult brain

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Apathy in Parkinson’s Disease and Implications for Underlying Pathophysiology;Journal of Clinical Medicine;2024-04-11

2. First‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers;Clinical Pharmacology in Drug Development;2021-06-12

3. Clinical Trial Highlights – Parkinson’s Disease Cognition;Journal of Parkinson's Disease;2021-02-02

4. Correction to “(3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) – a Novel Cortical-Preferring Catecholamine Transmission – and Cognition-Promoting Agent”;Journal of Pharmacology and Experimental Therapeutics;2020-08-31